KCM
ORKA

Kennedy Capital Management’s Oruka Therapeutics ORKA Stock Holding History

Kennedy Capital Management’s Portfolio ORKA Stock Details ORKA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.2M Buy
126,366
+77,680
+160% +$2.7M 0.13% 245
2025
Q4 		$1.48M Buy
48,686
+420
+0.9% +$11.7K 0.03% 449
2025
Q3 		$928K Sell
48,266
-16,660
-26% -$247K 0.02% 508
2025
Q2 		$728K Sell
64,926
-823
-1% -$8.58K 0.02% 530
2025
Q1 		$675K Buy
65,749
+5,255
+9% +$65.5K 0.02% 559
2024
Q4 		$1.17M Buy
+60,494
New +$1.48M 0.03% 580

Other funds holding ORKA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Kennedy Capital Management's ORKA Position: Q1 2026 in Review

Kennedy Capital Management increased its Oruka Therapeutics (ORKA) stake by 160% in Q1 2026, buying an estimated $2.7M and bringing the position to 126,366 shares worth $6.2M. The position accounts for 0.13% of the portfolio, ranked #245.

Kennedy Capital Management first reported a position in ORKA in Q4 2024 and has held it in 6 quarters since. 184 funds tracked by Wall St. Rank hold ORKA as of Q1 2026.

  • Kennedy Capital Management held 126,366 shares of Oruka Therapeutics worth $6.2M as of Q1 2026.
  • Kennedy Capital Management bought 77,680 Oruka Therapeutics shares in Q1 2026, an estimated $2.7M.
  • Oruka Therapeutics made up 0.13% of Kennedy Capital Management's portfolio in Q1 2026, its #245 holding.
  • Kennedy Capital Management first reported a position in Oruka Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • 184 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q1 2026.

Based on Kennedy Capital Management's 13F filing for Q1 2026, filed 13 May 2026.